Mimetogen appoints Kim Brazzell CMO
This article was originally published in Scrip
Mimetogen Pharmaceuticals, a private company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases, has appointed Dr Kim Brazzell chief medical officer. Dr Brazzell will lead the development of Mimetogen's MIM-D3 pivotal programme for the treatment of dry eye. He previously held several executive positions at Inspire Pharmaceuticals, including executive vice-president of medical and scientific affairs.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.